Business Overview: Verano Holdings Corp. (OTC: VRNO)

---

Executive Summary

Verano Holdings Corp. is one of the largest vertically integrated, multi-state cannabis operators (MSOs) in the United States, with cultivation, processing, and retail operations spanning 13 states: Arizona, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia.

The company runs 160 retail dispensaries and 14 cultivation and processing facilities totaling over 1.1 million square feet of cultivation capacity, and sells both to its own retail network (branded primarily Zen Leaf and MÜV, with some locations under the Cannabist and SWC names from recent acquisitions) and wholesale to third-party retailers under brands including Encore, Avexia, Savvy, Essence, BITS, HYPHEN, and Swift Lifts.

Verano matters because it is a top-three market-share holder, by its own account, in essentially every category and state in which it operates, giving it scale that is rare in a federally illegal, state-by-state-licensed industry — but it also illustrates the sector's core problem: FY2025 revenue fell to $821.5 million from $878.6 million, and the company posted a $(257.9) million net loss, as price compression intensified across its mature markets.

---

1. Core Business Model & How They Work

Verano is organized around four pillars it names explicitly: cultivation, production, brand development, and retail. The model is a vertically integrated chain from seed to sale:

Cultivation (indoor/greenhouse) ➡️ Processing & Manufacturing (flower, vapes,
edibles, concentrates) ➡️ Brand Portfolio (Encore, Avexia, Savvy, etc.)
   ➡️ Wholesale Distribution (3rd-party dispensaries)  ➡️ Revenue
   ➡️ Owned Retail (Zen Leaf / MÜV dispensaries)        ➡️ Revenue

• State-by-state license moat: most of Verano's states cap the number of cultivation and retail licenses, so incumbency is itself a scarce asset — a new entrant usually cannot simply apply for a license.
• Revenue mix is split roughly 68% retail / 32% wholesale, and about 53% medical-use / 47% adult-use for FY2025, meaning Verano is still meaningfully exposed to medical-only states where reimbursement and patient dynamics differ from adult-use pricing.
• M&A as market entry: Verano has grown partly through acquisition (e.g., Cannabist AZ, CC East Virginia), which explains why some retail locations still carry acquired brand names rather than being rebannered immediately.

---

2. Business Segments

Verano does not break out formal GAAP reporting segments; its disclosure is organized by sales channel and state rather than discrete business units.

Verano Holdings Corp.
├── Retail (Zen Leaf / MÜV / Cannabist / SWC) ~68% of revenue
│     └── 160 dispensaries across 13 states
└── Wholesale (branded flower, vapes, edibles, concentrates) ~32% of revenue
      └── Sold to 3rd-party dispensaries in states where Verano cultivates

State concentration is meaningful: Florida (~28%), Illinois (~14%), and New Jersey (~11%) of FY2025 consolidated sales together account for more than half of revenue, so any single state's regulatory or pricing shift (e.g., new license issuance in Florida, price compression in Illinois) has an outsized effect on the whole company.

---

3. Key Offerings

---

4. Competitive Landscape

Verano names its most direct competitors explicitly in its 10-K: fellow vertically integrated multi-state operators Green Thumb Industries, Cresco Labs, Curaleaf Holdings, and Trulieve Cannabis Corp. It also faces competition from well-capitalized out-of-state operators seeking to enter its markets, and — importantly — from the illicit and unregulated hemp-derived cannabinoid market, which undercuts licensed operators on price without bearing licensing or tax costs.

                High Vertical Integration
                          │
   Trulieve ●             │             ● Verano / Curaleaf
   (SE concentration)     │             (broad multi-state footprint)
                          │
Low Price ────────────────┼──────────────── High Price / Premium
                          │
   Illicit/hemp market ●  │             ● Green Thumb (brand-led)
                          │
                Low Vertical Integration

All five major MSOs compete on the same structural axis: state-capped licenses create regional moats, but once a market matures (as in Illinois or Florida), price compression becomes the dominant competitive dynamic regardless of brand strength. Verano's response, per management, has been to defend top-three share positions in most categories rather than chase share through further price cuts.

---

5. Strategic Strengths & Risks

Strengths:

• License scarcity moat: state caps on cultivation/retail licenses make several of Verano's positions effectively non-replicable in the near term.
• Scale across 13 states: few MSOs match Verano's breadth, which supports purchasing power and brand leverage even as margins compress.
• Top-three share in most categories/states per BDSA data cited by the company, reducing the risk of being squeezed out entirely even in a price war.

Risks:

• Federal illegality: cannabis remains a Schedule I substance; Verano cannot access normal banking, interstate commerce, or federal tax deductions (280E), which structurally compresses net margins versus any ordinary consumer business.
• Price compression: management explicitly cites "ongoing price compression and competition" as the main driver of FY2025's revenue decline — this is an industry-wide trend, not Verano-specific, as licensed supply has caught up with and exceeded demand in mature states like Illinois.
• Rescheduling uncertainty as a double-edged sword: CEO George Archos flagged that Verano is awaiting a final rule on federal rescheduling, which the company hopes will be "game-changing" — but rescheduling could also invite new, better-capitalized entrants or multi-state retailers (e.g., pharmacy chains) once federal barriers fall.
• Continued net losses: despite a narrower loss than 2024, Verano posted a $(257.9) million net loss in FY2025, driven partly by impairments tied to acquired assets whose value has not held up against falling wholesale prices.

---

6. Financial Overview

---

7. Summary Conclusion

Verano's moat is almost entirely regulatory: state-capped cannabis licenses in 13 states give it durable positions that a new entrant cannot simply buy or build quickly, and its scale lets it defend top-three share in most of its markets. But that same regulatory structure caps the industry's growth and keeps federal tax and banking burdens (280E) in place, so even a well-run, top-tier MSO like Verano is posting GAAP net losses and shrinking revenue as licensed supply catches up with demand in its biggest states. The single biggest forward swing factor is federal rescheduling: it could relieve the 280E tax burden and improve margins meaningfully, but it could also erode the state-license moat that is currently Verano's main source of competitive protection.